References

Ajjan RA, Cummings MH, Jennings P, Leelarathna L, Rayman G, Wilmot EG. Optimising use of rate-of-change trend arrows for insulin dosing decisions using the FreeStyle Libre flash glucose monitoring system. Diab Vasc Dis Res. 2019; 16:(1)3-12

Anyanwagu U, Olaoye H, Jennings P Continuous subcutaneous insulin infusion (CSII) therapy at Derby Teaching Hospitals: sustained benefits in glucose control. Diabet Med. 2017; 34:(8)1154-1157

Beran D, Ewen M, Laing R. Constraints and challenges in access to insulin: a global perspective. Lancet Diabetes Endocrinol. 2016; 4:(3)275-285

Four Challenges of Life with Type 1 in Ghana. 2016. https://www.t1international.com/blog/2016/03/28/four-challenges-life-type-1-ghana/ (accessed 7 December 2021)

Bliss M. Rewriting medical history: Charles Best and the Banting and Best myth. J Hist Med Allied Sci. 1993; 48:(3)253-274

Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial. BMJ. 2002; 325:(7367)746-746

Gough S, Narendran P. Insulin and insulin treatment, 5th edn. In: Holt R, Cockram C, Flyvbjerg A, Goldstein B (eds). Hoboken: John Wiley & Sons; 2017

Herkert D, Vijayakumar P, Luo J Cost-related insulin underuse among patients with diabetes. JAMA Intern Med. 2019; 179:(1)112-114

Ionescu-Tirgoviste C, Buda O. Nicolae Constantin Paulescu: the first explicit description of the internal secretion of the pancreas. Acta Med Hist Adriat. 2017; 15:(2)303-322

Jennings P, Hussain S. Do-it-yourself artificial pancreas systems: a review of the emerging evidence and insights for healthcare professionals. J Diabetes Sci Technol. 2020; 14:(5)868-877

Karamitsos DT. The story of insulin discovery. Diabetes Res Clin Pract. 2011; 93:S2-S8

Li A. Rethinking the “discovery” of insulin. CMAJ. 2021; 193:(42)E1636-E1637

Luo J, Kesselheim AS, Greene J, Lipska KJ. Strategies to improve the affordability of insulin in the USA. Lancet Diabetes Endocrinol. 2017; 5:(3)158-159

Nathan DM The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care. 2014; 37:(1)9-16

National Institute for Health and Care Excellence. Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus. 2008. https://www.nice.org.uk/guidance/ta151 (accessed 15 December 2021)

Pfiester E, Braune K, Thieffry A, Ballhausen H, Gajewska KA O'Donnell S. Costs and underuse of insulin and diabetes supplies: findings from the 2020 T1International cross-sectional web-based survey. Diabetes Res Clin Pract. 2021; 179

Rajkumar SV. The High Cost of Insulin in the United States: An Urgent Call to Action. Mayo Clin Proc. 2020; 95:(1)22-28

Rosenfeld L. Insulin: discovery and Controversy. Clin Chem. 2002; 48:(12)2270-2288

Schadewaldt H. The history of diabetes mellitus. In: von Engelhardt D (ed). Berlin: Springer-Verlag; 1989

Tattersall RB. The history of diabetes mellitus, 5th edn. In: Holt R, Cockram C, Flyvbjerg A, Goldstein B (e). Hoboken: John Wiley & Sons; 2017

Tibaldi JM. Evolution of insulin development: focus on key parameters. Adv Ther. 2012; 29:(7)590-619

Insulin for diabetes: 100 years of therapy

02 May 2022
Volume 4 · Issue 5

Abstract

January 2022 marks 100 years since insulin was first successfully used to treat diabetes in humans. Everyone with type 1 diabetes – except those who have received pancreas or islet-cell transplants – and more than half of people with type 2 diabetes use insulin to manage their diabetes. Instead of being seen as a death sentence, type 1 diabetes is now seen as a long-term condition that can be self-managed for people with access to insulin and glucose monitoring technology. However, many people living with diabetes around the world are still unable to access affordable insulin, technologies and the support needed to self-manage their diabetes.

On the 23 January 2022 we will celebrate the 100th anniversary of insulin successfully being used to treat diabetes in humans. This development marked a new era in the management of diabetes.

Before the discovery of insulin, the prognosis for people living with diabetes was very poor. People with diabetes followed various diets like the ‘meat diet’ that severely restricted carbohydrates or the ‘starvation diet’ that advocated total fasting. These diets had limited success in preventing deaths from ‘diabetic comas’, known today as diabetic ketoacidosis. Diabetic ketoacidosis is caused by extremely high glucose levels due to a lack of insulin (Schadewaldt, 1989).

In the last 100 years, insulin has become widely used to manage various forms of diabetes. Everyone with type 1 diabetes, except those who have received pancreas or islet-cell transplants, and more than half of people with type 2 diabetes use insulin to manage their diabetes (Gough and Narendran, 2017). For many people with access to insulin, being diagnosed with type 1 diabetes is no longer a death sentence. Instead, it is seen as a long-term condition that can be self-managed for people with access to insulin and glucose monitoring technology.

Register now to continue reading

Thank you for visiting Journal of Prescribing Practice and reading some of our peer-reviewed resources for prescribing professionals. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to our clinical or professional articles

  • New content and clinical newsletter updates each month